PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference – Unaudited 2023 total revenue of $946 million, representing 35% year-over-year growth – – Regulatory filings in the EU and US for sepiapterin in PKU, a potential $1 billion global commercial opportunity, remain on track for 2024 – – Multiple study readouts planned for 2024, including 12-month interim data from the PIVOT-HD study of PTC518 in HD patients – SOUTH PLAINFIELD, N.J., Jan. 8, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its commercial progress and R&D pipeline at the 42nd Annual J.P. Morgan Healthcare Conference today, Monday, January 8, at 10:30am EST/7:30am PST. Matthew Klein, M.D., Chief Executive Officer of PTC Therapeutics, will provide an update on 2023 accomplishments and highlight potential 2024 value-creating milestones. Preliminary 2023 unaudited financial results and 2024 financial guidance will also be provided. The presentation is being webcast live on the Events and Presentations page of the Investors section of PTC Therapeutics website at www.ptcbio.com. “2023 was a transformational year for PTC as we made necessary and important changes to become a leaner, more focused and financially stronger company positioned for future success,” said Matthew B. Klein, M.D., Chief Executive Officer of PTC. “We look forward to a successful 2024, with anticipated key global regulatory submissions for our PKU program and multiple data readouts, including from our PTC518 HD program.” Key 2023 Corporate Highlights: • Unaudited net product revenue of $661 million in 2023 representing 23% year-over-year growth. • Strong year-over-year growth for the Duchenne muscular dystrophy (DMD) franchise, with unaudited net product revenue of $355 million for Translarna™ (ataluren) and $255 million for Emflaza® (deflazacort) in 2023. • Translarna growth was driven by new patients in existing geographies and continued geographic expansion. • Emflaza growth was due to continued new prescriptions, high compliance, and more favorable access. • PTC announced positive readouts from key programs in its clinical pipeline in 2023: • Highly statistically significant and clinically meaningful results in the Phase 3 registration-directed APHENITY clinical trial of sepiapterin in adult and pediatric patients with PKU. • Achievement of all key objectives of the readout of 12-week interim data in the PIVOT-HD study of PTC518 in HD. • PTC announced strategic portfolio prioritizations, which resulted in reductions in both operating expenses and headcount of approximately 25% and 30%, respectively. • In October, PTC finalized a royalty agreement, in which Royalty Pharma acquired additional royalties of Evrysdi for $1.0 billion upfront. The agreement included options for PTC to sell the remainder of its royalties of Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date, less royalties received by PTC. PTC maintains all economics associated with up to $250 million in the remaining commercial sales milestones associated with Evrysdi global net sales. The

proceeds from the financing were used to retire all outstanding debt obligations with Blackstone Life Sciences. 2024 Potential Key Clinical and Regulatory Events: • Submission of an MAA to the EMA for sepiapterin for the treatment of PKU is expected in the first quarter. • Submission of an NDA to the FDA for sepiapterin for the treatment of PKU is expected no later than the third quarter. • Results from 12-month interim data from the PIVOT-HD trial of PTC518 in HD patients are expected in the second quarter. • Submission of a BLA to the FDA for Upstaza for the treatment of AADC deficiency is expected in the first quarter. • Topline results from the CardinALS trial of utreloxastat in ALS are expected in the fourth quarter. • PTC expects the CHMP opinion from the re-examination procedure of the negative opinion on the Translarna conditional marketing authorization renewal in late January 2024, with ratification of that opinion by the European Commission 67 days later. • FDA meeting for Translarna to align on the specific contents of a potential NDA resubmission is scheduled for the first quarter. • FDA meeting for vatiquinone to discuss how the MOVE-FA data along with additional clinical and preclinical data could support an NDA submission in FA is scheduled for the first quarter. • Scientific advice feedback from the EMA on a potential submission of vatiquinone for conditional marketing authorization for Friedreich ataxia is expected in the first quarter. Unaudited 2023 Financial Results: • Total unaudited net revenue for full year 2023 was approximately $946 million. • Total unaudited net product revenue for full year 2023 was approximately $661 million. • DMD franchise unaudited revenue for full year 2023 was approximately $610 million, including unaudited net product revenue for Translarna of approximately $355 million and for Emflaza of approximately $255 million. • PTC expects to report approximately $278 million for full year 2023 collaboration and royalty revenue associated with Evrysdi. PTC is currently in the process of finalizing its financial results for the 2023 fiscal year. The above information is based on preliminary unaudited information and management estimates for the full year 2023, subject to the completion of PTC's financial closing procedures. Evrysdi royalty revenue estimates are based on internal estimates. 2024 Financial Guidance: • PTC anticipates total revenues for the full year 2024 to be between $600 million and $850 million. • PTC anticipates GAAP R&D and SG&A expense for the full year 2024 to be between $740 and $835 million. • PTC anticipates Non-GAAP R&D and SG&A expense for the full year 2024 to be between $660 and $755 million, including expected R&D expense milestone payments of up to $65 million and excluding estimated non-cash, stock-based compensation expense of $80 million. • PTC anticipates up to $90 million of payments for the full year 2024 upon achievement of potential regulatory success-based milestones from previous acquisitions, of which up to $65 million will be recorded as R&D operating expense.

Non-GAAP Financial Measures: In this press release, the financial results and financial guidance of PTC are provided in accordance with GAAP and using certain non-GAAP financial measures. In particular, the non-GAAP financial measures exclude non-cash, stock-based compensation expense. These non-GAAP financial measures are provided as a complement to financial measures reported in GAAP because management uses these non-GAAP financial measures when assessing and identifying operational trends. In management's opinion, these non-GAAP financial measures are useful to investors and other users of PTC's financial statements by providing greater transparency into the historical and projected operating performance of PTC and the company's future outlook. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. Quantitative reconciliations of the non-GAAP financial measures to their respective closest equivalent GAAP financial measures are included in the table below. PTC Therapeutics, Inc. Reconciliation of GAAP to Non-GAAP Projected Full Year 2024 R&D and SG&A Expense (in millions) Low End of Range High End of Range Projected GAAP R&D and SG&A Expense $ 740 $ 835 Less: Projected Non-Cash, Stock-Based Compensation Expense 80 80 Projected non-GAAP R&D and SG&A Expense $ 660 $ 755 PTC Therapeutics, Inc. Reconciliation of GAAP Projected Full Year 2024 Milestone Payments (in millions) Projected GAAP R&D Expense Related Milestone Payments $ 65 Projected GAAP Contingent Consideration Payable Related Milestone Payments 25 Total Projected GAAP Milestone Payments $ 90 Acronyms: AADC: Aromatic I-Amino Acid Decarboxylase ALS: Amyotrophic Lateral Sclerosis BLA: Biologics License Application CHMP: Committee for Medicinal Products for Human Use DMD: Duchenne Muscular Dystrophy EMA: European Medicines Agency FDA: Food and Drug Administration MAA: Marketing Authorization Application NDA: New Drug Application PKU: Phenylketonuria R&D: Research and Development SG&A: Selling, General and Administrative SMA: Spinal Muscular Atrophy About PTC Therapeutics, Inc. PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare

disorders. PTC's ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. PTC's mission is to provide access to best-in-class treatments for patients who have little to no treatment options. PTC's strategy is to leverage its strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients. PTC believes this allows it to maximize value for all its stakeholders. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Instagram, Facebook, Twitter, and LinkedIn. For More Information: Investors Kylie O'Keefe +1 (908) 300-0691 kokeefe@ptcbio.com Media Jeanine Clemente +1 (908) 912-9406 jclemente@ptcbio.com Forward-Looking Statements: This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including the information provided under the heading "2024 Financial Guidance", including with respect to (i) 2024 total revenue guidance, (ii) 2024 GAAP and non-GAAP R&D and SG&A expense guidance and (iii) 2024 acquisition related milestone payment guidance, and statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses, commercialization and other matters with respect to its products and product candidates; PTC's strategy, future operations, future financial position, future revenues, projected costs; the extent, timing and financial aspects of our strategic pipeline prioritization and reductions in workforce; and the objectives of management. Other forward-looking statements may be identified by the words, "guidance", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions. PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC's products or product candidates that PTC commercializes or may commercialize in the future; PTC's ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in Brazil, Russia, the European Economic Area (EEA) and other regions, including whether the European Medicines Agency (EMA) determines in the re-examination process that the benefit-risk balance of Translarna authorization supports renewal of such authorization; PTC's ability to use the results of Study 041, a randomized, 18-month, placebo-controlled clinical trial of Translarna for the treatment of nmDMD followed by an 18-month open-label extension, which was a specific obligation to continued marketing authorization in the EEA, to support a renewal of the conditional marketing authorization for Translarna for the treatment of nmDMD in the EEA; PTC's ability to utilize results from Study 041 to support a marketing approval for Translarna for the treatment of nmDMD in the United States; whether investigators agree with PTC's interpretation of

the results of clinical trials and the totality of clinical data from our trials in Translarna; expectations with respect to Upstaza, including any regulatory submissions and potential approvals, commercialization, manufacturing capabilities, the potential achievement of development, regulatory and sales milestones and contingent payments that PTC may be obligated to make; expectations with respect to the commercialization of Evrysdi under our SMA collaboration; expectations with respect to the commercialization of Tegsedi and Waylivra; the timing of and actual expenses incurred in connection with the discontinuation of PTC's preclinical and early research programs in gene therapy and reductions in workforce, which may be in different periods and may be materially higher than estimated; the savings that may result from the discontinuation of PTC's strategic pipeline prioritization and reductions in workforce, which may be materially less than expected; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC's products and product candidates; PTC's scientific approach and general development progress; the potential financial impact and benefits of PTC's leased biologics manufacturing facility; PTC's ability to satisfy its obligations under the terms of its lease agreements, including for its leased biologics manufacturing facility; the sufficiency of PTC's cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the "Risk Factors" section of PTC's most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Translarna, Emflaza, Upstaza, Evrysdi, Tegsedi or Waylivra. The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.

PTC Therapeutics – JP Morgan 2024 Matthew B. Klein, MD CEO PTC Therapeutics 2024 Patient Living with PKU

PTC Therapeutics – JP Morgan 2024 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historic fact, are forward-looking statements, including statements with respect to 2024 total revenue guidance, 2024 operating expenditure guidance and 2024 acquisition related milestone payment guidance, and statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses, commercialization and other matters with respect to its products and product candidates; PTC's strategy, future operations, future financial position, future revenues, projected costs; the extent, timing and financial aspects of our strategic pipeline prioritization and reductions in workforce; and the objectives of management. Other forward-looking statements may be identified by the words, "guidance", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions. PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC's products or product candidates that PTC commercializes or may commercialize in the future; PTC's ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in Brazil, Russia, the European Economic Area (EEA) and other regions, including whether the European Medicines Agency (EMA) determines in the re-examination process that the benefit-risk balance of Translarna authorization supports renewal of such authorization; PTC's ability to use the results of Study 041, a randomized, 18-month, placebo-controlled clinical trial of Translarna for the treatment of nmDMD followed by an 18-month open-label extension, which was a specific obligation to continued marketing authorization in the EEA, to support a renewal of the conditional marketing authorization for Translarna for the treatment of nmDMD in the EEA; PTC's ability to utilize results from Study 041 to support a marketing approval for Translarna for the treatment of nmDMD in the United States; whether investigators agree with PTC's interpretation of the results of clinical trials and the totality of clinical data from our trials in Translarna; expectations with respect to Upstaza, including any regulatory submissions and potential approvals, commercialization, manufacturing capabilities, the potential achievement of development, regulatory and sales milestones and contingent payments that PTC may be obligated to make; expectations with respect to the commercialization of Evrysdi under our SMA collaboration; expectations with respect to the commercialization of Tegsedi and Waylivra; the timing of and actual expenses incurred in connection with the discontinuation of PTC's preclinical and early research programs in gene therapy and reductions in workforce, which may be in different periods and may be materially higher than estimated; the savings that may result from the discontinuation of PTC's strategic pipeline prioritization and reductions in workforce, which may be materially less than expected; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC's products and product candidates; PTC's scientific approach and general development progress; the potential financial impact and benefits of PTC's leased biologics manufacturing facility; PTC's ability to satisfy its obligations under the terms of its lease agreements, including for its leased biologics manufacturing facility; the sufficiency of PTC's cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the "Risk Factors" section of PTC's most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Translarna, Emflaza, Upstaza, Evrysdi, Tegsedi or Waylivra. The forward-looking statements contained herein represent PTC's views only as of the date of this presentation and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this presentation except as required by law. Forward Looking Statements 2

3 PTC Therapeutics – JP Morgan 2024 2023

4 PTC Therapeutics – JP Morgan 2024 Building the PTC of the Future Focus Right Sizing OPEX Reduction Royalty Financing

PTC Therapeutics – JP Morgan 2024 PTC Mission Remains Patient Focused 5 Discover Develop Commercialize Transformative therapies for patients with rare diseases

PTC Therapeutics – JP Morgan 2024 PTC Strategy Leverages Innovative Science, Passionate Team and Strong Cash Position 6 Innovative Science Ferroptosis and Inflammation Splicing

PTC Therapeutics – JP Morgan 2024 PTC Strategy Leverages Innovative Science, Passionate Team and Strong Cash Position 7 Therapeutic Neurology Metabolism Expertise* Innovative Science * Unesbulin (PTC596) development discontinued

PTC Therapeutics – JP Morgan 2024 PTC Strategy Leverages Innovative Science, Passionate Team and Strong Cash Position 8 Global Commercial Infrastructure Therapeutic Expertise* Innovative Science Europe United States Asia Pacific Latin America Middle East & North Africa

PTC Therapeutics – JP Morgan 2024 Robust Portfolio to Support Growth & Value Creation 9 Research Splicing Platform Ferroptosis and Inflammation Platform SCA-3 MAP-tau Undisclosed (Movement Disorders) Undisclosed (Neurodegenerative Diseases) Undisclosed (Pediatric Neurodevelopment Disorders) Development Utreloxastat (ALS) PTC518 (HD) Sepiapterin (PKU) Vatiquinone (FA) Undisclosed (Myopathies) Phase 1 Phase 2 Phase 2/3 Phase 3 Phase 1 Phase 2 Phase 2/3 Phase 3 NDA Stage Phase 1 Phase 2 Phase 2/3 Phase 1 Phase 2 Phase 1

PTC Therapeutics – JP Morgan 2024 Unaudited DMD Franchise Net Product Revenue ~$610M Strong Commercial Performance and Growth in 2023 10 2023 Unaudited Total Revenue ~$946M

PTC Therapeutics – JP Morgan 2024 Strong R&D Execution and Value Creation in 2023 11 *Primary endpoint did not meet statistical significance Positive interim data for PIVOT-HD Highly statistically significant and meaningful APHENITY results Positive upright stability and fatigue scale results for MOVE-FA* Clinical Additional approvals enabling continued geographic expansion Additional LATAM approvals enabling geographic expansion Additional LATAM approvals enabling geographic expansion Regulatory

PTC Therapeutics – JP Morgan 2024 2024 Revenue and OPEX Guidance *Non-GAAP measure which excludes estimated non-cash, stock-based compensation expense of approximately $80 million. GAAP R&D and SG&A expense for the full year 2024 is anticipated to be 12 between $740 and $835 million. The Company anticipates up to $65 million of payments upon achievement of potential regulatory success-based milestones from previous acquisitions. OPEX Guidance* $660-755M includes regulatory milestones up to $65M 2024 Total Revenue Guidance $600-$850M

PTC Therapeutics – JP Morgan 2024 Key Expected Regulatory & Clinical Milestones in 2024 13 Q1 Q2 Q3 Q4 Sepiapterin PKU MAA Submission Sepiapterin PKU NDA Submission Upstaza BLA Submission t Topline Results Utreloxastat Interim Results PTC518

PTC Therapeutics – JP Morgan 2024 Sepiapterin PKU Program Patient Living with PKU

15 PTC Therapeutics – JP Morgan 2024 Phe, phenylalanine; PKU, phenylketonuria. APHENITY Results Demonstrate Meaningful Benefit of Sepiapterin in PKU Patients The primary endpoint was reached in the placebo-controlled portion of the study with statistically significant reductions in blood Phe levels (p < 0.0001) A substantial reduction in blood Phe levels from baseline was observed in both the primary analysis population (63%) and the subset of participants with classical PKU (69%) 94% of patients ≥ 12 years with blood Phe ≥ 600 µmol/L at baseline achieved a reduction in blood Phe to reach guideline target Sepiapterin was well tolerated with no serious adverse events

PTC Therapeutics – JP Morgan 2024 0 50 100 150 200 Baseline W1-W2 W3-W4 W5-W6 W7-W8 W9-W10 W11-W12 W13-W14 W15-W16 W17-W18 W19-W20 W21-W22 W23-W24 W25-W26 RDA* 40 Dietary Phe Intake and Blood Phe Levels Over Time Phe Consumption (mg/kg/day) 16 Sepiapterin Enables Increased Dietary Phe Intake in PKU Patients -200 0 200 400 600 360 Blood Phe Level (µmol/L) *Recommended dietary allowance Results based on interim data cut and not full data set Dietary Phe Consumption (mg/kg/day) Blood Phe Level (µmol/L) N= 40

PTC Therapeutics – JP Morgan 2024 APHENITY Results Support Potential for Sepiapterin to Address Broad PKU Population 17 Therapy-Naive Patients Including Classical PKU Patients Who Are Not Well Controlled by Current Therapies Patients Who Have Failed on Current Therapies Greater than $1 Billion Potential Revenue Opportunity

PTC Therapeutics – JP Morgan 2024 Global Regulatory Submissions and Launch Preparation Planned for 2024 18 Global Regulatory Submissions Global Launch Sequence and Continued Launch Preparation

PTC Therapeutics – JP Morgan 2024 PTC518 HD Program

PTC Therapeutics – JP Morgan 2024 Key Attributes of PTC518 Drive Differentiation 20 Orally bioavailable Titratable and reversible Reduces HTT mRNA and protein in the CNS and periphery Uniform lowering in key regions of the brain Highly selective and specific Not effluxed, penetrates blood brain barrier

PTC Therapeutics – JP Morgan 2024 PIVOT-HD Study Design 21 3 months 9 months 5 mg PTC518 R 10 mg PTC518 N = ~30 N = ~30 N = ~30 Part A Part B Placebo 5 mg PTC518 10 mg PTC518 Primary Endpoints • Safety and tolerability of PTC518 • Percent reduction in HTT mRNA and protein in blood Secondary Endpoints • Percent reduction in mHTT protein in CSF • Changes in neurofilament light chain (NfL) in plasma and CSF • Change in brain volume on volumetric MRI imaging

22 PTC Therapeutics – JP Morgan 2024 12-Week Interim Data Met Key Objectives PTC518 treatment resulted in dose-dependent lowering of HTT mRNA and protein levels in blood cells PTC518 demonstrated desired CSF exposure with higher concentrations of free drug in the CSF than plasma PTC518 was well tolerated with no treatment-related serious adverse events and no reports of peripheral neuropathy CSF NfL levels remained stable after 12 weeks of treatment with no treatment-related spikes

PTC Therapeutics – JP Morgan 2024 12 Month Data Update to Include Blood, CSF and Radiographic Biomarkers 23 Safety and tolerability of PTC518 Percent reduction in HTT mRNA and protein in blood Percent reduction in mHTT protein in CSF Changes in neurofilament light chain (NfL) in plasma and CSF Change in brain volume on volumetric MRI imaging Interim Results Expected Q2 2024

PTC Therapeutics – JP Morgan 2024 Vatiquinone FA Program Patient Living with FA

PTC Therapeutics – JP Morgan 2024 Meaningful Clinical Results in MOVE-FA 25 *Study primary endpoint Change from Baseline to Week 72 Analysis Placebo Vatiquinone Difference P-value mFARS Total* 2.83 1.22 -1.61 0.144 Upright Stability 2.99 1.73 -1.26 0.021 Bulbar 0.22 0.040 -0.18 0.044 Fatigue Scale (MFIS) 4.29 -0.76 -5.05 0.025 Upcoming Regulatory Interactions in Q1 2024 Live Type C Meeting EMA Scientific Advice Feedback

PTC Therapeutics – JP Morgan 2024 Utreloxastat ALS Program

PTC Therapeutics – JP Morgan 2024 Preclinical and Clinical Evidence Confirm Link Between ALS and Ferroptosis Pathway 27 Iron accumulation, a marker of ferroptosis, within spinal cord lesions has been reported as an early event in ALS pathogenesis1 Fe3+ Oxidized lipids and the 15-lipoxygenase end-product, 4-hydroxy-2,3- nonenal (4-HNE), levels are elevated in ALS patients2 4-HNE Overexpression of GPX4 protects against motor neuron death3 Targeting ferroptosis in ALS in vivo and clinical studies demonstrates improved function and survival ALS, amyotrophic lateral sclerosis; GPX4, glutathione peroxidase 4. 1. Li Q, et al. Front Neurol. 2022;13:791300. 2. Simpson EP, et al. Neurology. 2004;62:1758–1765. 3. Moreau C, et al. Antioxid Redox Signal. 2018;29:742–748.

PTC Therapeutics – JP Morgan 2024 CardinALS Study Design 28 Key Endpoints • Change in ALS-FRS Scale • Respiratory Function • Survival Utreloxastat 250 mg BID Utreloxastat 250 mg BID 24 Weeks 28 Weeks Placebo-Controlled Phase Open-Label Extension Phase Placebo Study Timeline • Enrollment Completed: Q1 2024 • Topline Results: Q4 2024 N = ~ 100 N = ~ 200 8 Weeks Observational Run-in Phase R

29 PTC Therapeutics – JP Morgan 2024 2023

30 PTC Therapeutics – JP Morgan 2024